gamma-Secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity.

Because Notch signaling is implicated in colon cancer tumorigenesis and protects cells from apoptosis by inducing prosurvival targets, it was hypothesized that inhibition of Notch signaling with gamma-secretase inhibitors (GSI) may enhance the chemosensitivity of colon cancer cells. We first show that the Notch-1 receptor, as well as its downstream target Hes-1, is up-regulated with colon cancer progression, similar to other genes involved in chemoresistance. We then report that chemotherapy induces Notch-1, as oxaliplatin, 5-fluorouracil (5-FU), or SN-38 (the active metabolite of irinotecan) induced Notch-1 intracellular domain (NICD) protein and activated Hes-1. Induction of NICD by oxaliplatin was caused by an increase in the activity and expression of gamma-secretase complex, as suppression of the protein subunit nicastrin with small interfering RNA (siRNA) prevented NICD induction after oxaliplatin. Subsequent inhibition of Notch-1 signaling with a sulfonamide GSI (GSI34) prevented the induction of NICD by chemotherapy and blunted Hes-1 activation. Blocking the activation of Notch signaling with GSI34 sensitized cells to chemotherapy and was synergistic with oxaliplatin, 5-FU, and SN-38. This chemosensitization was mediated by Notch-1, as inhibition of Notch-1 with siRNA enhanced chemosensitivity whereas overexpression of NICD increased chemoresistance. Down-regulation of Notch signaling also prevented the induction of prosurvival pathways, most notably phosphoinositide kinase-3/Akt, after oxaliplatin. In summary, colon cancer cells may up-regulate Notch-1 as a protective mechanism in response to chemotherapy. Therefore, combining GSIs with chemotherapy may represent a novel approach for treating metastatic colon cancers by mitigating the development of chemoresistance.

[1]  Thomas D. Wu,et al.  Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. , 2006, Cancer cell.

[2]  Sathish Kumar Mungamuri,et al.  Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53. , 2006, Cancer research.

[3]  Joonhee Kim,et al.  PEN-2 Overexpression Induces γ-Secretase Protein and its Activity with Amyloid β-42 Production , 2007, Neurochemical Research.

[4]  P. Rao,et al.  Notch and Schwann cell transformation , 2004, Oncogene.

[5]  R. L. Hayward,et al.  Enhanced oxaliplatin-induced apoptosis following antisense Bcl-xl down-regulation is p53 and Bax dependent: Genetic evidence for specificity of the antisense effect. , 2004, Molecular cancer therapeutics.

[6]  I. Kola,et al.  Positive and Negative Regulation of the γ-Secretase Activity by Nicastrin in a Murine Model* , 2003, Journal of Biological Chemistry.

[7]  T. Park,et al.  Activated Notch1 interacts with p53 to inhibit its phosphorylation and transactivation , 2007, Cell Death and Differentiation.

[8]  J. Garlick,et al.  Notch1 is a p53 target gene involved in human keratinocyte tumor suppression through negative regulation of ROCK1/2 and MRCKalpha kinases. , 2007, Genes & development.

[9]  A. Gazdar,et al.  Oxygen concentration determines the biological effects of NOTCH-1 signaling in adenocarcinoma of the lung. , 2007, Cancer research.

[10]  M. Monden,et al.  Role of p21waf1/cip1 in effects of oxaliplatin in colorectal cancer cells , 2005, Molecular Cancer Therapeutics.

[11]  N. Anderson,et al.  Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways. , 2007, Journal of the National Cancer Institute.

[12]  A. Capobianco,et al.  Induction of Cyclin D1 Transcription and CDK2 Activity by Notchic: Implication for Cell Cycle Disruption in Transformation by Notchic , 2001, Molecular and Cellular Biology.

[13]  A. Sarin,et al.  The Anti-apoptotic Effect of Notch-1 Requires p56lck-dependent, Akt/PKB-mediated Signaling in T Cells* , 2004, Journal of Biological Chemistry.

[14]  L. L. Reed,et al.  Notch inhibition in Kaposi's sarcoma tumor cells leads to mitotic catastrophe through nuclear factor-κB signaling , 2007, Molecular Cancer Therapeutics.

[15]  Yulia Nefedova,et al.  Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. , 2004, Blood.

[16]  J. Aster,et al.  A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Chelsea C Pinnix,et al.  Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression. , 2006, Cancer research.

[18]  Pier Paolo Di Fiore,et al.  NUMB controls p53 tumour suppressor activity , 2008, Nature.

[19]  Min Xu,et al.  Presenilin 1 is linked with gamma-secretase activity in the detergent solubilized state. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[20]  C. Manetopoulos,et al.  Effects of the histone deacetylase inhibitor valproic acid on Notch signalling in human neuroblastoma cells , 2005, British Journal of Cancer.

[21]  J. Aster,et al.  c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. , 2006, Genes & development.

[22]  Arie Perry,et al.  Notch1 and Notch2 Have Opposite Effects on Embryonal Brain Tumor Growth , 2004, Cancer Research.

[23]  Masafumi Nakamura,et al.  Gamma-secretase inhibitors enhance taxane-induced mitotic arrest and apoptosis in colon cancer cells. , 2008, Gastroenterology.

[24]  R. Tibshirani,et al.  Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia. , 2007, Blood.

[25]  I. Shih,et al.  Notch Signaling, γ-Secretase Inhibitors, and Cancer Therapy: Figure 1. , 2007 .

[26]  M. Fey,et al.  The Notch pathway in ovarian carcinomas and adenomas , 2005, British Journal of Cancer.

[27]  F. Ciardiello,et al.  Sequence-dependent inhibition of human colon cancer cell growth and of prosurvival pathways by oxaliplatin in combination with ZD6474 (Zactima), an inhibitor of VEGFR and EGFR tyrosine kinases , 2006, Molecular Cancer Therapeutics.

[28]  J. Aster,et al.  The multifaceted role of Notch in cancer. , 2007, Current opinion in genetics & development.

[29]  P. Nair,et al.  Coexpression of Notch1 and NF-kappaB signaling pathway components in human cervical cancer progression. , 2007, Gynecologic oncology.

[30]  F. Alimirah,et al.  Restoration of p53 expression in human cancer cell lines upregulates the expression of Notch1: implications for cancer cell fate determination after genotoxic stress. , 2007, Neoplasia.

[31]  P. V. van Diest,et al.  Differential Notch and TGFβ Signaling in Primary Colorectal Tumors and Their Corresponding Metastases , 2008, Cellular oncology : the official journal of the International Society for Cellular Oncology.

[32]  Herb Chen,et al.  Valproic acid activates notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells. , 2007, The oncologist.

[33]  S. Varambally,et al.  JAGGED1 Expression Is Associated with Prostate Cancer Metastasis and Recurrence , 2004, Cancer Research.

[34]  Zhiwei Wang,et al.  Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. , 2006, Cancer research.

[35]  J. Best,et al.  A novel series of potent γ-secretase inhibitors based on a benzobicyclo[4.2.1]nonane core , 2005 .

[36]  Min Xu,et al.  Presenilin 1 is linked with γ-secretase activity in the detergent solubilized state , 2000, Neurobiology of Aging.

[37]  G. Lockwood,et al.  High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. , 2005, Cancer research.

[38]  R. Clarke,et al.  Aberrant Activation of Notch Signaling in Human Breast Cancer , 2006 .

[39]  I. Mook‐Jung,et al.  DNA damage-inducing agent-elicited γ-secretase activity is dependent on Bax/Bcl-2 pathway but not on caspase cascades , 2007, Cell Death and Differentiation.

[40]  M. Katoh,et al.  Notch signaling in gastrointestinal tract (review). , 2007, International journal of oncology.

[41]  Govind Bhagat,et al.  Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia , 2007, Nature Medicine.

[42]  K. Somasundaram,et al.  Activated Notch1 Inhibits p53-Induced Apoptosis and Sustains Transformation by Human Papillomavirus Type 16 E6 and E7 Oncogenes through a PI3K-PKB/Akt-Dependent Pathway , 2003, Journal of Virology.

[43]  Gordon K Smyth,et al.  Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2004, Statistical applications in genetics and molecular biology.

[44]  L. Ellis,et al.  Chronic Oxaliplatin Resistance Induces Epithelial-to-Mesenchymal Transition in Colorectal Cancer Cell Lines , 2006, Clinical Cancer Research.

[45]  James D. Griffin,et al.  Growth Suppression of Pre-T Acute Lymphoblastic Leukemia Cells by Inhibition of Notch Signaling , 2003, Molecular and Cellular Biology.

[46]  Freddy Radtke,et al.  Notch signaling is a direct determinant of keratinocyte growth arrest and entry into differentiation , 2001, The EMBO journal.

[47]  Rafael A Irizarry,et al.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.

[48]  J. Liao,et al.  Serveur Académique Lausannois SERVAL serval.unil.ch , 2022 .

[49]  L. L. Reed,et al.  Gamma secretase inhibitor blocks Notch activation and induces apoptosis in Kaposi's sarcoma tumor cells , 2005, Oncogene.